Abgenix and Elan enter Xenomouse technology collaboration to generate fully human antibody therapy for neurological diseases.(Brief Article): An article from: BIOTECH Patent News

This digital document is an article from BIOTECH Patent News, published by Biotech Patent News on January 1, 2000. The length of the article is 2625 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Abgenix and Elan enter Xenomouse technology collaboration to generate fully human antibody therapy for neurological diseases.(Brief Article)
Publication:BIOTECH Patent News (Newsletter)
Date: January 1, 2000
Publisher: Biotech Patent News
Volume: 14 Issue: 1 Page: NA

Article Type: Brief Article

Distributed by Thomson Gale